ALX-S002

The University of Texas MD Anderson Cancer Center (Houston, TX) › ALX-S002

ALX-S002

A Phase 1 Study to Evaluate Intratumoral Doxorubicin Exposure Following Administration of Aldoxorubicin or Doxorubicin · Phase I
The University of Texas MD Anderson Cancer Center (Houston, TX) · Dr. Reyes

screened

AEs

0

Serious

0

Dropout signal

–

Adverse events

0

No adverse events recorded. New events are triaged from the Safety tab.

Data queries

0

No data queries. Open queries would appear here for this patient.